Akebia Therapeutics (AKBA) Common Equity (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Common Equity data on file, last reported at $27.4 million in Q1 2026.

• Common Equity for Q1 2026 came in at $27.4 million, up 11.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.4 million (up 11.37% YoY), and the FY2025 annual result was $32.6 million, up 166.3% from the prior year.
• Common Equity declined to $27.4 million in Q1 2026 per AKBA's latest filing, from $32.6 million in the prior quarter.
• Over five years, Common Equity peaked at $58.9 million in Q2 2022 and troughed at -$50.4 million in Q3 2024.
• A 5-year average of -$1.5 million and a median of $5.2 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity tumbled 684.78% in 2023, then jumped 190.18% in 2025.
• A 5-year view of Common Equity shows it stood at $5.2 million in 2022, then plunged by 684.78% to -$30.6 million in 2023, then tumbled by 60.82% to -$49.2 million in 2024, then jumped by 166.3% to $32.6 million in 2025, then fell by 16.05% to $27.4 million in 2026.
• Business Quant data shows AKBA's Common Equity at $27.4 million in Q1 2026, $32.6 million in Q4 2025, and $41.6 million in Q3 2025.